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Abstract 
The present work is aimed at investigations of the effects of various 
stabilizers and process parameters on the properties of budesonide 
(glucocorticoid steroid) loaded PLGA (Poly-dl-lactide-co-glycolide) 
nanoparticles. Budesonide loaded PLGA nanoparticles were 
prepared following high pressure emulsification- solvent evaporation 
technique. The effects of three different stabilizers like 
polyvinylalcohol (PVA), carbomer (Carbopol 980) and poloxamer 
(Lutrol F-68) are used during emulsification process were studied. 
Investigations were also carried out regarding influences of different 
homogenization parameters (pressure and number of cycles) on the 
properties of various nanoparticles. For comparison, nanoparticles 
were prepared without the treatment of high pressure also. Various 
properties of nanoparticles subjected to investigations include, 
particle size, polydispersity index, drug loading, encapsulation 
efficiency and the drug release profile. These properties were found 
to be strongly influenced by the type of stabilizer, homogenization 
pressure and the number of cycles. Amongst three stabilizers, PVA 
found to produce comparatively smallest nanoparticles than 
poloxamer and carbomer. The nanoparticles prepared without high 
pressure homogenization found to posse’s larger size and high values 
of polydispersity index especially with the stabilizers carbomer and 
poloxamer. The low drug loading of nanoparticles found, could be 
resulted due to high pressure promoted drug diffusion from the 
protoparticles during the emulsification process and the 
characteristics of the outer water phase of emulsion. Faster drug 
release was observed from the nanoparticles obtained after high 
pressure emulsification as compared to those prepared without 
pressure homogenization of emulsion. 
keywords: Budesonide, nanoparticles, polyvinylalcohol, carbomer, 
poloxamer, homogenization. 
Introduction 
Budesonide is a glucocorticoid steroid used for 
the treatment of asthma, non-infectious rhinitis 
(including hay fever and other allergies), and for 
treatment and prevention of nasal polyposis. 
Additionally, it is used for crohn's disease 
(inflammatory bowel disease). Budesonide has a 
high first pass metabolism and half life of 2 to 3 
hours (for children plasma half life is still 
shorter), thus, making it a suitable candidate for 
particulate drug delivery system. 
 
Biodegradable particulate drug delivery systems 
have been widely studied mainly for aerosol, 
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parenteral, oral or ocular applications [1-3]. 
Several methods for their preparation were 
developed, but the most popular is the 
emulsification-solvent evaporation method [4] 
and its modification, the double emulsion-solvent 
evaporation method [5]. The main difficulty of 
this technique is the necessity to optimize various 
parameters in order to obtain particles of suitable 
size with narrow size distribution. The stirring 
speed used during emulsification as well as the 
nature and concentration of selected stabilizers 
have been extensively examined [6,7]. However, 
the high stirring speed and even sonication are 
not sufficient to achieve a narrow particle size 
distribution. Therefore, the high pressure 
homogenization technique was successfully 
adapted [8]. This method is mainly used for 
production of microemulsion [9-11] and liposome 
[12,13], but there are found to be only a small 
number of studies concerning polymeric 
nanoparticle preparations [14&15]. 
 
The main aim of the present work was to 
investigate the effect of different stabilizers and 
homogenization parameters on the various 
properties of budesonide loaded nanoparticles 
meant for ocular purposes which were prepared 
by a high- pressure emulsification-solvent 
evaporation method. It has been observed that 
large particles may irritate the eye. Consequently 
smaller particles are preferred for ophthalmic 
delivery systems [16]. Additionally, Calvo et al., 
have reported that poly ("-caprolactone) 
nanoparticles (0.20–0.25 µm) improve the ocular 
bioavailability of indomethacin rather than poly 
("-caprolactone) microparticles (6 µm) [17]. 
Thus, one of the most important characteristics of 
nanoparticles is their size. For this reason, the 
influence of homogenization parameters, like 
pressure and number of cycles applied, on the 
nanoparticle properties were investigated in 
detail. The effects of the nature of different 
stabilizers like polyvinylalcohol (PVA), carbomer 
(Carbopol 980) and poloxamer (Lutrol F-68) on 
the nanoparticle size were also studied. PVA is 
often used as a stabilizing agent for the 
emulsification-solvent evaporation method. 
Carbopol and poloxamer were chosen as 
stabilizers because of their mucoadhesive 
properties. It is well known that the ocular 
bioavailability can be improved using 
mucoadhesive particulate drug delivery systems 
[18]. 
 
Materials and Methods 
Materials 
Budesonide was obtained from Ranbaxy (Noida, 
India). Poly (dl-lactide-co-glycolide) (PLGA, 
Resomer RG 503, lactic:glycolic ratio 52:48, Mw 
40 000) was obtained from Boehringer Ingelheim 
(Ingelheim, Germany). Polyvinylalcohol (PVA) 
(Average Mw 30 000–70 000) was supplied by 
Sigma Chemical Co. (St. Louis, USA). Methanol 
and acetonitrile (HPLC grade) were from Across 
Organics (New Jersey, USA) and Methylene 
Chloride from Aldrich (Gillingham, UK). 
Carbopol 980 NF was obtained from BF 
Goodrich (Cleveland, USA) and Poloxamer 188 
(Lutrol F-68) was from BASF (Ludwig- shafen, 
Germany). 
 
Preparation of Nanoparticles 
Budesonide loaded PLGA nanoparticles were 
prepared by the combination of double 
emulsification and homogenization procedure. 
PLGA (1g) was dissolved in 10 ml of methylene 
chloride and dispersed in an aqueous solution of 
budesonide (2.5% w/v). The emulsification was 
carried out by sonication for 1 min at 80 W (Lark 
India-02, India) [19]. The resulting emulsion was 
poured into 50 ml of an aqueous stabilizer 
solution and was sonicated for 30 s. PVA (1% 
w/v), carbopol (0.012% w/v) and poloxamer 
(2.2% w/v) were used as stabilizers. The W/O/W 
emulsions were then subjected to a high pressure 
homogenization using a microfluidizer (M-110L, 
Microfluidics, Newton, USA) and were treated 
with one or three cycles at an operating pressure 
of 100 and 500 bar. Finally, the homogenized 
emulsions were added to aqueous solutions of 
stabilizer to allow the simultaneous evaporation 
of the methylene chloride. The concentrations of 
PVA, carbopol and poloxamer in these water 
solutions were 0.33, 0.004 and 0.73% (w/v), 
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respectively. The evaporation was carried out at 
room temperature under stirring at 700 rpm 
(Remi, Munchen, Germany). The resulting 
suspensions were cooled down at -18°C and then 
freeze dried. For comparison, nanoparticles of the 
W/O/W emulsion were prepared without high-
pressure treatment. 
 
Evaluation of Nanoparticles 
Particle size 
Particle sizes of nanoparticles were determined 
by photon correlation spectroscopy with a 
Zetasizer 3000 (Malvern Instruments, Malvern, 
UK). The freeze dried samples were diluted 25 
times with distilled water before measurements. 
Each sample was determined four times and 
average values were calculated.  
 
Drug loading and Encapsulation efficiency 
Accurately weighed freeze dried nanoparticles 
(20 mg) were dispersed in 10 ml distilled water 
by sonication for 10 min. The samples were 
centrifuged at 3000 rpm for 3 h and the drug 
content in the supernatant fluid was determined 
by an HPLC method. The HPLC system was a 
Gilson 321 pump (Jasco, Japan). The mobile 
phase consisted of a water/methanol mixture 
(97:3, v/v) and potassium dihydrogen phosphate 
(5%, w/v). Determinations were performed using 
a column Bondapak C18 (Waters) at a flow rate 
of 2 ml/min and sensitivity 0.005%, respectively. 
Budesonide was detected at 216 nm and its 
concentration was calculated according to the 
calibration curve prepared under the same 
conditions. The measurements were made in 
duplicate. The encapsulation efficiency (EE) for 
all samples was estimated using the equation: 
 
Encapsulation efficiency (%) =  
¼ (actual drug loading/theoretical drug loading) x100 
 
In vitro release studies  
The in vitro drug release studies were carried out 
in duplicate using diffusion cells. The acceptor 
and donor compartments of the cells were 
separated by a dialysis membrane (Mw cut off 
12,000–14,000 D, Medicell, UK). The 
membranes were washed with distilled water for 
30 min before diffusion experiments. The 
nanoparticles (20 mg) were placed as an aqueous 
suspension in the donor compartments of the 
cells. The acceptor compartments were filled with 
18 ml distilled water and stirred magnetically at 
200 rpm. At suitable time intervals aliquots of 0.8 
ml were withdrawn from the acceptor 
compartments and replaced by the same volumes 
of fresh distilled water. The concentrations of 
samples were determined following the above 
described HPLC method. 
 
 
Figure. 1. Influence of PVA on particle size of budesonide loaded nanoparticles. 
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Figure. 2. Influence of Carbopol on particle size of budesonide loaded nanoparticles. 
 
 
 
Figure. 3. Influence of Poloxamer on particle size of budesonide loaded nanoparticles. 
 
 
Results and Discussion 
Nanoparticle size 
The results of determination of particle size and 
polydispersity index of various nanoparticles are 
summarized in Table. 1. The data showed that the 
nanoparticle size and polydispersity index depend 
strongly on the homogenization pressure and 
number of cycles (Figures.1-3). The higher the 
pressure applied resulting in smaller the size of 
the nanoparticles. In addition, the increase of 
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number of cycles even from one cycle to three 
cycles, contributed to particle size reduction. 
These observations were valid for all the 
formulations investigated. In comparison, the 
nanoparticles formulated without homogenization 
pressure showed larger in size and high values of 
polydispersity index (Table 1). However, the 
nanoparticles prepared without homogenization 
pressure using poloxamer as stabilizer possessed 
comparatively smaller particle size and the 
nanoparticles prepared without pressure using 
PVA as stabilizer maintained a low value of 
polydispersity index. The studies performed with 
nanoparticles prepared using PVA as a stabilizer 
showed a small dependence of the particle size on 
the pressure and the number of cycles. Contrarily 
the pressures as well as number of cycles have 
significant impact on the mean particle size of 
nanoparticles prepared with carbopol and 
poloxamer.  
 
These particles demonstrated a wide size range, 
from 446.6–1802.7 nm in the case of carbopol, 
and from 452.3–875.4 nm for poloxamer 
respectively. However, due to application of the 
homogenization pressure, their size drastically 
dropped down around 300 nm when the emulsion 
containing protoparticles was treated with 500 
bar pressure for three cycles. The same effect was 
observed on the polydispersity index of both the 
nanoparticle series. The increase in pressure and 
especially the number of cycles reduced the 
polydispersity index. 
 
Table. 1. Effect of nature of stabilizers, homogenization pressure and number of cycles on mean diameter and polydispersity 
index of prepared nanoparticles. 
Stabilizer Homogenization pressure and number of cycles Mean Diameter (nm) Polydispersity index
PVA Without pressure 332.5 ± 2.5 0.083 
 100 bar, 1 cycle 283.1 ± 2.2 0.121 
 100 bar, 3 cycles 231.8 ± 1.4 0.097 
 500 bar, 1 cycle 231.3 ± 0.7 0.082 
 500 bar, 3 cycles 203.8 ± 5.5 0.308 
Carbopol Without pressure 1125.3 ± 776.5 0.783 
 100 bar, 1 cycle 631.4 ± 1.72 0.635 
 100 bar, 3 cycles 365.7 ± 2.61 0.542 
 500 bar, 1 cycle 467.0 ± 4.23 0.661 
 500 bar, 3 cycles 308.9 ± 10.8 0.053 
Poloxamer Without pressure 572.4 ± 206.6 0.802 
 100 bar, 1 cycle 691.7 ± 189.4 0.765 
 100 bar, 3 cycles 424.5 ± 13.4 0.528 
 500 bar, 1 cycle 467.0 ± 4.21 0.809 
 500 bar, 3 cycles 304.3 ± 34.8 0.307 
 
Table. 2. Effect of nature of stabilizer and process parameters on Drug loading and Entrapment efficiency of prepared 
nanoparticles 
 Without pressure 100 bar, 1 cycle 100 bar, 3 cycles 500 bar, 1 cycle 500 bar, 3 cycles
Stabilizer Drug 
Loading  
(%) 
EE 
(%) 
Drug  
Loading 
 (%) 
EE 
(%)
Drug  
Loading  
(%) 
EE 
(%) 
Drug  
Loading  
(%) 
EE  
(%) 
Drug  
Loading  
(%) 
EE  
(%) 
PVA 2.93 ± 0.02 61.5 0.79 ± 0.3 16.6 0.66 ± 0.16 13.9 0.21 ± 0.06 4.4 0.95 ± 0.35 20.0 
Carbopol 3.34 ± 0.01 70.2   3.82 ± 0.02 80.5 3.62 ± 0.19 76.1 3.01±  0.05 63.2 1.41 ± 0.12 29.6 
Poloxamer 1.54 ± 0.04  32.3   1.47 ± 0.01 30.9 1.33 ± 0.05 16.0 1.33 ± 0.05 27.9 0.80 ± 0.04 16.8 
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Drug loading and encapsulation efficiency 
The results of drug loading and encapsulation 
efficiency of nanoparticles prepared without or 
under high pressure are presented in Table 2. 
Generally, drug loading and encapsulation 
efficiency decreases with the application of 
pressure. 
 
For particles made with PVA as a stabilizer, the 
encapsulation efficiency went down from 61.5% 
for those prepared without pressure to 13.9–
20.0% for those obtained under pressure. Similar 
trend was also observed for particles formulated 
in presence of carbopol and poloxamer as 
stabilizers. For these nanoparticles, well 
pronounced differences in the encapsulation 
efficiency were found between the formulation 
obtained at highest pressure (500 bar) and those 
which were formulated without pressure. For all 
the formulations drug loading and encapsulation 
efficiency were increased approximately two 
times when no pressure was applied. This 
phenomenon was probably due to the enhanced 
diffusion of the hydrophilic budesonide 
molecules out of the emulsion droplets during 
their size reduction under pressure. Similar 
results were reported by Soriano et al. (1995) 
[20]. They found that albumin-loaded PLGA 
microspheres manufactured under pressure had 
lower encapsulation efficiency than the samples 
produced by only sonication. 
 
The properties of the outer aqueous phase of the 
W/O/W emulsion may also influence drug 
diffusion out of polymeric droplets. As it could 
be seen, different drug loading was measured for 
nanoparticles prepared with PVA, carbopol and 
poloxamer as stabilizers at similar pressures 
(Table. 2). However, the concentrations of 
stabilizers were chosen so as to give an equal 
viscosity to the water phases. Moreover, the 
stabilizers also have different surface active 
properties. Therefore, the differences of 
interfacial tension probably have influenced drug 
diffusion from polymeric droplets to the outer 
water phase. 
 
 
 
Figure. 4. The effect of pressure (three cycles) on the encapsulation efficiency (EE) and size of nanoparticles prepared with 
PVA. 
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Figure. 5. The effect of pressure (three cycles) on the encapsulation efficiency (EE) and size of nanoparticles prepared with 
carbopol. 
 
 
 
Figure. 6. The effect of pressure (three cycles) on the encapsulation efficiency (EE) and size of nanoparticles prepared with 
PVA as an emulsifier. 
 
Drug loading of the larger particles produced 
without or at the lower pressure was higher for all 
the preparations. This is due to available surface 
area of the particles, which was depending on 
their size. In absence of pressure the larger 
protoparticles provide minimum possibility for 
drug diffusion out to the external water phase. 
However, the nanoparticles made with PVA 
showed a narrow size distribution. Despite their 
similar sizes, drug loading dramatically dropped 
when pressure was applied (Figures. 4-6). The 
results illustrated the fact that particle size was 
not the only factor responsible for the low drug 
loading value. The low drug loading could be due 
to two reasons. First, the high pressure promoted 
drug diffusion out of protoparticles during 
emulsification was either by size reduction or by 
shear forces and second, the characteristic of the 
outer water phase of the emulsion also might 
have influenced the drug loading of 
nanoparticles. 
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Figure. 7. Influence of manufacturing parameters on in-vitro drug release process from nanoparticles prepared with PVA. 
 
 
Figure. 8. Influence of manufacturing parameters on in-vitro drug release process from nanoparticles prepared with carbopol. 
 
 
Figure. 9. Influence of manufacturing parameters on in-vitro drug release process from nanoparticles prepared with poloxamer. 
 
In vitro drug release 
Comparatively faster drug release was detected 
from nanoparticles obtained after homogenization 
of the W/O/W emulsion than those prepared 
without homogenization (Figures. 7-9). It was 
more pronounced for the batches formulated at 
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the lower pressure. The fastest release of 
budesonide occurred from all nanoparticles 
treated at 100 bar pressure which was 
independent of either the number of cycles 
applied or the nature of the stabilizer used. These 
release profiles were unexpected because of small 
sizes of nanoparticles formulated at the higher 
pressure (500 bar). Consequently, their ultimate 
surface area became larger favouring a faster 
release of the drug. Taking into account of 
different values of homogenization pressure 
applied, the present study revealed a difference 
possibly occurred between density and structure 
of the nanoparticles. This explanation could be 
deduced from the comparison between the drug 
releases of two batches of formulation of similar 
size. Both nanoparticle samples made with PVA 
as stabilizer had similar size [Table 1]. However, 
the drug release was faster from the low-pressure 
homogenized particles (100 bar, 3 cycles) 
compared to the higher-pressure homogenized 
particles (500 bar, 1 cycle). Therefore, the 
observations revealed that the main factor 
influencing drug release property of nanoparticles 
was the pressure applied during homogenization 
of protoparticles. 
 
Conclusion 
Budesonide loaded PLGA nanoparticles were 
prepared by high-pressure emulsification-solvent 
evaporation technique. The effects of three 
different stabilizers on the various properties of 
budesonide loaded nanoparticles were studied. 
The higher the pressure as well as the number of 
cycles applied, the smaller the sizes of 
nanoparticles were produced. Simultaneously 
increase in homogenization pressure and number 
of cycles resulted in reduction of polydispersity 
index. The lower drug loading and encapsulation 
efficiency of nanoparticles were observed due to 
high pressure promoted drug diffusion from the 
protoparticles and the characteristics of outer 
aqueous phase of the emulsion. The in-vitro drug 
release profile of nanoparticles was influenced by 
the pressure applied during homogenization of 
protoparticles. Amongst three stabilizers used in 
the study PVA found to be comparatively better 
in all aspects. The present study may prove the 
way for formulation of budesonide loaded PLGA 
nanoparticles meant for various therapeutic uses 
through the ocular delivery system.  
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